These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8395368)

  • 1. A lack of anti-hypertensive effect of an orally effective V1 receptor antagonist, OPC-21268, in end-stage renal disease.
    Nakayama M; Yamada K; Nakano H; Miura Y; Suzuki S; Tuchida H; Yoshida S
    Clin Nephrol; 1993 Jul; 40(1):58-9. PubMed ID: 8395368
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
    Miura Y; Yamada K; Nakayama M; Nakano H; Suzuki S; Tsuchida H; Yoshida S
    Clin Nephrol; 1993 Jul; 40(1):60-1. PubMed ID: 8395369
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus.
    Nishikawa T; Omura M; Iizuka T; Saito I; Yoshida S
    Arzneimittelforschung; 1996 Sep; 46(9):875-8. PubMed ID: 8876935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasopressin (ADH)].
    Hirai A; Uchida D; Yoshida S
    Nihon Rinsho; 1992 Dec; 50(12):2893-900. PubMed ID: 1337114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
    Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat.
    Tachikawa K; Yokoi H; Nagasaki H; Arima H; Murase T; Sugimura Y; Miura Y; Hirabayashi M; Oiso Y
    Am J Physiol Endocrinol Metab; 2003 Dec; 285(6):E1161-6. PubMed ID: 12915399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
    Yoshitomi K; Naruse M; Hanaoka K; Yamamura Y; Imai M; Kurokawa K
    Kidney Int Suppl; 1996 Jun; 55():S177-82. PubMed ID: 8743549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats.
    Anderson IK; Drew GM
    Br J Pharmacol; 1998 Nov; 125(6):1236-46. PubMed ID: 9863652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
    Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A
    Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats.
    Yamada Y; Yamamura Y; Chihara T; Onogawa T; Nakamura S; Yamashita T; Mori T; Tominaga M; Yabuuchi Y
    Hypertension; 1994 Feb; 23(2):200-4. PubMed ID: 8307629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.
    Chihara T; Nakamura S; Onogawa T; Yamashita T; Yamamura Y; Mori T; Tominaga M; Yabuuchi Y
    Jpn J Pharmacol; 1995 Jul; 68(3):345-7. PubMed ID: 7474558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
    Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA
    Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes.
    Kawano Y; Matsuoka H; Nishikimi T; Takishita S; Omae T
    Am J Hypertens; 1997 Nov; 10(11):1240-4. PubMed ID: 9397242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.
    Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
    Prog Brain Res; 2008; 170():519-25. PubMed ID: 18655905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
    Stam WB; Van der Graaf PH; Saxena PR
    Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ACE inhibitors and the kidney].
    Hörl WH
    Wien Med Wochenschr; 1996; 146(11):231-4; discussion 234-5. PubMed ID: 8928521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats.
    Okada H; Suzuki H; Kanno Y; Yamamura Y; Saruta T
    Clin Sci (Lond); 1994 Apr; 86(4):399-404. PubMed ID: 8168333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.